COVID-19

Novavax, Inc announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial. The study enrolled 29,960 participants across 119 sites in the U.S. and Mexico to evaluate efficacy, safety and immunogenicity, with an emphasis on recruiting a representative population of communities and demographic groups most impacted by the disease.

Patanjali Pharma Pvt. Ltd. is a Startup which has been incubated with SINE (Society for Innovation & Entrepreneurship), IIT Bombay, Powai, Mumbai, India.  It has been working on major thrust areas like diagnostics and therapeutics for COVID-19, Drug Resistant Tuberculosis, Malnutrition and other infectious disorders.

“It is a piece of misinformation that subsequent waves of the COVID-19 pandemic are going to cause severe illness in children. There is no data - either from India or globally - to show that children will be seriously infected in subsequent waves.” This was informed by Director, All India Institute of Medical Sciences (AIIMS) Delhi, Dr. Randeep Guleria, during a media briefing on COVID-19, held at National Media Centre, PIB Delhi today.

New research identified a novel interaction between the SARS-CoV-2 spike protein and the galectin-3-binding protein (LGALS3BP) which could be a new therapeutic anti-viral target. The research also found the presence of detectable viral RNA in blood in COVID-19 patients is a strong predictor of mortality.

Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) can trace its origins to the Ecole de Medicine de Pondicherry established by the French Government in 1823. In 1956 foundation for new medical college was laid and in 1964, hospital was inaugurated. JIPMER became an institution of national importance under the Ministry of Health and Family Welfare, Government of India in the year 2008. It is an institution established for teaching, research and patient care in the area of health. JIPMER spreads over 192 acres.

The COVID-19 Vaccine Janssen has been given regulatory approval by the Medicines and Healthcare products Regulatory Agency . This is the fourth COVID-19 vaccine to be authorised by the UKs independent regulator and is the first to be approved for protection against COVID-19 with a single dose.

Moderna, Inc a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Phase 2/3 study of its COVID-19 vaccine (mRNA-1273) in adolescents has met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination. In the study, no cases of COVID-19 were observed in participants who had received two doses of the Moderna COVID-19 vaccine using the primary definition.

Roche India and Cipla Limited announced that the first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients. Cipla will distribute the product by leveraging its strong distribution strengths across the country. The drug will be available through leading hospitals and COVID treatment centers.

Moderna, Inc a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan granted special approval under article 14-3 of the Pharmaceuticals and Medical Devices Act for emergency use of Moderna’s mRNA COVID-19 vaccine, now known as COVID-19 Vaccine Moderna Intramuscular Injection, in Japan. Distribution by Takeda in Japan will begin immediately.